Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

29 Jan 2019

• By John Davis

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.

Stepping stones — Alexion is taking steps to add further indications to its next-generation complement inhibitor • Source: Shutterstock

Alexion Pharmaceuticals Inc.'s progress in developing a next-generation successor for its aging blockbuster, Soliris (eculizumab) are being viewed in a positive light by analysts, who have been upbeat about late-stage clinical results released earlier this week involving the longer-acting successor, Ultomiris, in a second potential indication.

Top-line data from a Phase III study of Ultomiris (ravulizumab-cwvz) in complement-inhibitor naive patients with atypical hemolytic uremic syndrome (aHUS), released by Alexion on Jan. 28, were spotlighted by Alexion and analysts as showing beneficial effects in the condition, data which may help protect the company's $3.5bn complement franchise. The results come after the Dec

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

24 Apr 2025

• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

24 Apr 2025

• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

31 Mar 2025

• By Kevin Grogan

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)

06 Jan 2025

• By Joseph Haas

Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.